



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/782,899	02/23/2004	Minoru Fujimori	2004_0290	5937

7590 03/28/2006

Thomas J. Kowalski, Esq.
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151

EXAMINER

WHITEMAN, BRIAN A

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 03/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/782,899

Applicant(s)

FUJIMORI ET AL.

Examiner

Brian Whiteman

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 February 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 4, 6, 7, 10-14, 16, 19-22, 24, 25 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 22 is/are allowed.
- 6) ☒ Claim(s) 4, 6, 7, 10-14, 16, 19, 21, 24 and 25 is/are rejected.
- 7) ☒ Claim(s) 20 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Final Rejection

Claims 4, 6, 7, 10-14, 16, 19-22, 24, and 25 are pending.

Applicant's traversal, the amendment to claims 4, 10-14, 16, 21, 22, 24, and 25, the amendment to the specification and the cancellation of claims 1-3, 5, 8, 9, 15, 17, 18, 23, 26, and 27 filed on 2/1/06 is acknowledged and considered by the examiner.

Election/Restrictions

This application contains DNA coding for a protein having anti-tumor activity in claims 4, 14, 16, 21, and 25 drawn to a species nonelected with traverse in Paper No. 6/15/05. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Objections

Applicant is advised that should claim 4 be found allowable, claim 14 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Applicant is advised that should claim 24 be found allowable, claim 25 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing,

Art Unit: 1635

despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim 20 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 4, 6, 7, 10, 11, 14, 16, 21, 24, and 25 remain rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for specifically delivering to tumor tissues under anaerobic conditions in an individual with cancer a genetically modified bacterium, comprising administering a genetically modified bacterium to an individual with cancer, wherein the genetically modified bacterium is a *Bifidobacterium longum*, which comprises an expression vector comprising a DNA sequence coding for an anti-tumor protein, and does not reasonably provide enablement for a method for specifically delivering to tumor tissues under anaerobic conditions in an individual with cancer a genetically modified bacterium, wherein the genetically modified bacterium selected from the group consisting of a genus of *Bifidobacterium*. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in *In re Wands*, 858 F.2d 731, 8USPQ2d 1400 (Fed. Cir. 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The field of the invention is using a bacterium from the genus *Bifidobacterium* as a gene delivery vector comprising a gene used in a method of delivering the gene delivery vector to tumor tissues under anaerobic conditions.

The art of record for *Bifidobacterium* as exemplified by Yazawa et al. (Breast Cancer Research and Treatment, Vol. 66, pp. 156-170, 2001) teaches that:

Bifidobacterium is non-pathogenic bacteria found in the intestine of human and some other mammalian animals. These organisms are believed to have health-promoting properties for their host, including increase of the immune response, inhibition of carcinogenesis, and protection of the host against viral infections. However, despite increasing attention to this bacterium in many fields, little is known about its genetic property (page 165).

Furthermore, the state of the art for transforming bacterium from the genus *Bifidobacterium* is highly unpredictable as exemplified by Argnani et al. (IDS, Microbiology, Vol. 142, pp. 109-114). Argnani teaches:

Although electroporation technique has proven to be widely applicable to genetically transform bacterial strains, all *Bifidobacterium* so far examined have proved refractory to efficient and reproducible transformation (page 109).

Yazawa, whom teaches that, further supports this:

To be able to exploit the potential of these organisms for cancer gene therapy, detailed knowledge is required about such basic biological phenomena as cellular metabolism,

gene expression, protein secretion, and genetics. Yazawa further states that, studies on *Bifidobacterium* at the molecular level are severely limited in the absence of an efficient transformation. Recently, Matsumura and colleagues developed a system for convenient and reproducible genetic transformation of *B. longum* (page 169).

The applicants provide several working examples displaying the transformation of *Bifidobacterium longum* with a gene and the deliver of the genetically modified bacterium to tumor-bearing mice (pages 46-61). The delivery displayed that the bacterium specifically targeted the tumors (page 48). In addition, one example displays the production of a genetically modified bacterium comprising a cytosine deaminase (CD) gene and an example introducing the bacterium, which was specifically expressed only in tumor tissues under anaerobic conditions in tumor-bearing mice (pages 55-61). In view of the instant specification and the art of record for using *Bifidobacterium* as a gene delivery vector, the claimed invention is only enabled for producing and using the *Bifidobacterium longum* comprising a gene for use in specifically delivering to tumor tissues under anaerobic conditions in a mammal because the as-filed specification and the art of record do not provide sufficient guidance for one skilled in the art to reasonably extrapolate from using *Bifidobacterium longum* to using the genus *Bifidobacterium* without an undue amount of experimentation. The art of record display that studies on *Bifidobacterium* at the molecular level are severely limited in the absence of an efficient transformation. Therefore, the state of the art is considered unpredictable and the as-filed specification does not provide sufficient guidance for one skilled in the art to make and/or use a representative number of bacterium from the genus *Bifidobacterium* as gene delivery vectors.

As a result, it is not apparent how one skilled in the art determines, without undue experimentation, which of the claimed bacterium from the genus *Bifidobacterium* other than the *Bifidobacterium longum* can be genetically modified and used as a gene delivery vector, how is it apparent as to how one skilled in the art, without any undue experimentation, practices any nucleic acid delivery method as contemplated by the claims, particularly given the unpredictability of nucleic acid therapy as a whole and/or the doubts expressed in the art of record.

The court in Enzo 188 F.3d at 1374, 52 USPQ2d at 1138 states:

It is well settled that patent applications are not required to disclose every species encompassed by their claims, even in an unpredictable art. However, there must be sufficient disclosure, either through illustrative examples or terminology, to teach those of ordinary skill how to make and use the invention as broadly as it is claimed. In re Vaeck, 947 F.2d 48, 496 & n.23, 30 USPQ2d 1438, 1445 & n.23 (Fed. Cir. 1991)(citation omitted). Here, however, the teachings set forth in the specification provide no more than a “plan” or “invitation” for those of skill in the art to experiment...; they do not provide sufficient guidance or specificity as to how to execute that plan. See Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993); In re Wright, 999 F.2d...[1557], 1562, 27 USPQ2d...[1510], 1514. [Footnote omitted].

On this record, it is apparent that the specification provides no more than a plan or invitation in view of the art of record exemplifying the unpredictability of making and using the claimed species of *Bifidobacterium* (See Argnani), for those skilled in the art to further experiment with different species of claimed genus of *Bifidobacterium* so as to provide a therapeutic method of cancer gene therapy as intended by the as-filed specification at the time the invention was made.

See also Genentech Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1366, 42, USPQ2d 1001, 1005 (Fed. Cir. 1997)

(“Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable the public to understand and carry out the invention.”)

In view of the art of record and the lack of guidance provided by the specification, the specification does not provide reasonable detail for what protocols are required for successfully transfecting different species *Bifidobacterium*, and it would take one skilled in the art an undue amount of experimentation to reasonably extrapolate from the specification to the full breadth of the claimed invention. Therefore, the as-filed specification is not enabled for the full scope of the claimed invention.

In conclusion, the as-filed specification and claims coupled with the art of record at the time the invention was made only provide sufficient guidance and/or evidence to reasonably enable a method for specifically delivering to tumor tissues under anaerobic conditions in an individual with cancer a genetically modified bacterium, wherein the genetically modified bacterium is a *Bifidobacterium longum*, which comprises an expression vector comprising a DNA sequence coding for a protein. Given that efficiently transfecting a representative number of *Bifidobacterium* was unpredictable at the time the invention was made, and given the lack of sufficient guidance as to how to reasonably correlate efficiently transfecting *Bifidobacterium longum* to the other species of *Bifidobacterium* cited in the claims, one skilled in the art would have to engage in a large quantity of experimentation in order to practice the claimed invention based on the applicants' disclosure and the unpredictability of transfecting *Bifidobacterium*.

Applicant's arguments filed 2/1/06 have been fully considered but they are not persuasive.

In response to applicant's argument that the enablement rejection is moot because of the amendment to the claims to recite using a *Bifidobacterium longum*, the argument is not found

Art Unit: 1635

persuasive because the claims do not recite using a *Bifidobacterium longum*. Thus, the enablement rejection remains for the reasons of record.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 4, 6, 7, 10, 11, 12, 13, 14, 24, and 25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4, 6, 7, 10, 11, 12, 13, 14, and 24-25 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted step is: delivering a recombinant *Bifidobacterium* comprising a DNA encoding a protein to a tumor tissue under anaerobic condition to an individual with cancer. The active steps to complete the methods are missing from the claims.

Applicant's arguments filed 2/1/06 have been fully considered but they are not persuasive.

In response to applicant's argument that the 112 second paragraph rejection is moot because of the amendment to the claim, the argument is not found persuasive because the even though the preamble recites delivering the DNA to tumor tissue of an individual, the body of the claim does not recite the active step to complete the preamble of the claim.

The phrase "use of the method as in claim 4" in claims 24 is a relative term, which renders the claim indefinite. The phrase "use of the method as in claim 4" is not defined by the

Art Unit: 1635

claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The claims do not define the metes and bounds of the phrase. The claims do not define the term "used" and what way the method of claim 4 is being used.

Suggest amending claim 24 as follows: -- The method of claim 24, wherein the tumor tissues are solid tumors --.

Applicant's arguments filed 2/1/06 have been fully considered but they are not persuasive because applicants amended the claim with the suggested limitation but did not delete the phrase "used of the method as in claim 4" from the claim.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or non-obviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 4, 6, 7, 10, 12, 14, 16, 19, 21, 24, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yazawa et al. (Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 40, pp. 88, 1999) taken with Brown (AC). Yazawa teaches using *Bifidobacterium longum* as a gene delivery vector for treating cancer. However, Yazawa does not specifically teach introducing a DNA coding for a protein having an activity of converting a precursor of an anti-tumor substance into the anti-tumor substance into a tumor using *Bifidobacterium longum*.

However, at the time the invention was made, introducing a DNA coding for a protein having an activity of converting a precursor of an anti-tumor substance into the anti-tumor substance into a tumor using a genetically modified bacterium was well known to one of ordinary skill in the art as exemplified by Brown (columns 1-26). Brown teaches using a genetically modified bacterium to deliver an enzyme to the hypoxic/necrotic environment of a tumor and systemically administering a pro-drug, which is converted at the site of the tumor to the toxic agent by the enzyme (columns 25-26). The enzyme/prodrug combination can be

selected from following: nitroreductase/CB1954; cytosine deaminase/5-fluorocytosine; beta-glucuronidase/glucuronidated anticancer drugs (columns 5-6).

It would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to modify the teaching of Yazawa taken with Brown, namely to use a genetically modified *Bifidobacterium longum* comprising a nucleic acid sequence encoding a protein having an activity of converting a precursor of an anti-tumor substance into the anti-tumor substance in a method to treat tumor tissues under anaerobic conditions. One of ordinary skill in the art would have been motivated to introduce the DNA encoding a protein having an activity of converting a precursor of an anti-tumor substance into the anti-tumor substance into tumor tissues under anaerobic conditions using the genetically modified bacterium because the bacterium is a nonpathogenic anaerobic bacterium, which can selectively localize to solid tumors in an individual after systemic application and pro-drug cancer therapy was well known to one of ordinary skill in the art for treating tumor tissue.

In addition, it would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to modify the teaching of Yazawa taken with Brown, namely to use any enzyme/prodrug combination in the method to treat tumor tissues under anaerobic conditions. One of ordinary skill in the art would have been motivated, as a matter of designer's choice, to use an enzyme/prodrug combination selected from following: nitroreductase/CB1954; cytosine deaminase/5-fluorocytosine; beta-glucuronidase/glucuronidated anticancer drugs because the enzyme/prodrug combinations were well known to one of ordinary skill in the art for treating hypoxic tumor tissue.

In addition, it would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to combine the teaching of Yazawa taken with Brown, namely to use an expression vector that has a promoter and terminator that function in a Bifidobacterium. One of ordinary skill in the art would have been motivated to use a promoter and terminator that function in the Bifidobacterium because one of ordinary skill in the art understands that a promoter and a terminator are required for the vector to express the protein of interest.

Therefore the invention as a whole would have been *prima facie* obvious to one ordinary skill in the art at the time the invention was made.

Applicant's arguments filed 2/1/06 have been fully considered but they are not persuasive.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

In response to applicant's argument that in view of the technical common knowledge at the time of filing that genetic characteristics of the genus of *Bifidobacterium* was not known (no reproducible system of controlling factor, such as promoter to express protein encoded by the introduced gene in high concentration was not sufficient) one of ordinary skill in the art could not prepare a genetically modified *Bifidobacterium longum*, the argument is not found persuasive because while it is acknowledged that successfully transfecting a genus of *Bifidobacterium* is unpredictable, Matsumura (AM) teaches a shuttle vector that can successfully transformed *B.*

Art Unit: 1635

longum. Thus, one of ordinary skill in the art would have reasonable expectation of success for producing a genetically modified *B. longum* and use in a method of treating cancer in a patient.

The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965); In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997).

Response to Arguments

Applicant's arguments, see page 8, filed 2/1/06, with respect to 112 second paragraph rejection have been fully considered and are persuasive. The rejection of claims 1-3, 8, 9, 15, 17, and 18 has been withdrawn because of the cancellation of the claims.

Applicant's arguments, see page 8, filed 2/1/06, with respect to 102 rejection as being anticipated by Yazawa (AJ) have been fully considered and are persuasive. The rejection of claims 1-3, 8, 9, 12, 14, 16, 19, 21, and 24 has been withdrawn because of the Declaration under 1.132.

The Declaration under 37 CFR 1.132 filed 2/1/06 is sufficient to overcome the rejection of claims 1-3, 8, 9, 12, 14, 16, 19, 21, and 24 based upon 102(a) rejection. The inventors not listed on the publication joined the research group after the article was published.

Applicant's arguments, see pages 8-9, filed 2/1/06, with respect to 102 rejection as being anticipated by Babincova (AW) have been fully considered and are persuasive. The rejection of claims 1-3, 8, 9, 12, 14, 16, 19, 21, and 24 has been withdrawn because the applicants invented the subject matter (Yazawa, AJ) cited by Babincova before the date of the Babincova reference.

Applicant's argument, see page 9, filed 2/1/06, with respect to 102 rejection as being anticipated by Yazawa et al. (Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 40, pp. 88, 1999) have been fully considered and are persuasive. The rejection of Claims 1-3, 8, 12, 14, 15, 16, 19, 21, and 24 has been withdrawn because of Yazawa does not teach the bacterium comprising a DNA coding for a protein having an activity of a precursor of an antitumor substance into an antitumor substance.

Applicant's argument, see page 9, filed 2/1/06, with respect to 102 rejection as being anticipated by Matsumura et al. (AM) has been fully considered and are persuasive. The rejection of claims 16, 19, and 21 has been withdrawn because of the amendment to claim 16 to recited the bacterium comprising a DNA DNA coding for a protein having an activity of a precursor of an antitumor substance into an antitumor substance.

Conclusion

Claim 22 is in condition for allowance because the claim is free of the prior art of record.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period

Art Unit: 1635

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, acting SPE – Art Unit 1635, can be reached at (571) 272-0811.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Fax Center number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

BRIAN WHITEMAN
PATENT EXAMINER

